Afficher la notice abrégée

HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes

dc.rights.licenseopenen_US
dc.contributor.authorWANG, S. S.
dc.contributor.authorCARRINGTON, M.
dc.contributor.authorBERNDT, S. I.
dc.contributor.authorSLAGER, S. L.
dc.contributor.authorBRACCI, P. M.
dc.contributor.authorVOUTSINAS, J.
dc.contributor.authorCERHAN, J. R.
dc.contributor.authorSMEDBY, K. E.
dc.contributor.authorHJALGRIM, H.
dc.contributor.authorVIJAI, J.
dc.contributor.authorMORTON, L. M.
dc.contributor.authorVERMEULEN, R.
dc.contributor.authorPALTIEL, O.
dc.contributor.authorVAJDIC, C. M.
dc.contributor.authorLINET, M. S.
dc.contributor.authorNIETERS, A.
dc.contributor.authorDE SANJOSE, S.
dc.contributor.authorCOZEN, W.
dc.contributor.authorBROWN, E. E.
dc.contributor.authorTURNER, J.
dc.contributor.authorSPINELLI, J. J.
dc.contributor.authorZHENG, T.
dc.contributor.authorBIRMANN, B. M.
dc.contributor.authorFLOWERS, C. R.
dc.contributor.authorBECKER, N.
dc.contributor.authorHOLLY, E. A.
dc.contributor.authorKANE, E.
dc.contributor.authorWEISENBURGER, D.
dc.contributor.authorMAYNADIE, M.
dc.contributor.authorCOCCO, P.
dc.contributor.authorALBANES, D.
dc.contributor.authorWEINSTEIN, S. J.
dc.contributor.authorTERAS, L. R.
dc.contributor.authorDIVER, W. R.
dc.contributor.authorLAX, S. J.
dc.contributor.authorTRAVIS, R. C.
dc.contributor.authorKAAKS, R.
dc.contributor.authorRIBOLI, E.
dc.contributor.authorBENAVENTE, Y.
dc.contributor.authorBRENNAN, P.
dc.contributor.authorMCKAY, J.
dc.contributor.authorDELFAU-LARUE, M. H.
dc.contributor.authorLINK, B. K.
dc.contributor.authorMAGNANI, C.
dc.contributor.authorENNAS, M. G.
dc.contributor.authorLATTE, G.
dc.contributor.authorFELDMAN, A. L.
dc.contributor.authorDOO, N. W.
dc.contributor.authorGILES, G. G.
dc.contributor.authorSOUTHEY, M. C.
dc.contributor.authorMILNE, R. L.
dc.contributor.authorOFFIT, K.
dc.contributor.authorMUSINSKY, J.
dc.contributor.authorARSLAN, A. A.
dc.contributor.authorPURDUE, M. P.
dc.contributor.authorADAMI, H. O.
dc.contributor.authorMELBYE, M.
dc.contributor.authorGLIMELIUS, B.
dc.contributor.authorCONDE, L.
dc.contributor.authorCAMP, N. J.
dc.contributor.authorGLENN, M.
dc.contributor.authorCURTIN, K.
dc.contributor.authorCLAVEL, J.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMONNEREAU, Alain
dc.contributor.authorCOX, D. G.
dc.contributor.authorGHESQUIERES, H.
dc.contributor.authorSALLES, G.
dc.contributor.authorBOFETTA, P.
dc.contributor.authorFORETOVA, L.
dc.contributor.authorSTAINES, A.
dc.contributor.authorDAVIS, S.
dc.contributor.authorSEVERSON, R. K.
dc.contributor.authorLAN, Q.
dc.contributor.authorBROOKS-WILSON, A.
dc.contributor.authorSMITH, M. T.
dc.contributor.authorROMAN, E.
dc.contributor.authorKRICKER, A.
dc.contributor.authorZHANG, Y.
dc.contributor.authorKRAFT, P.
dc.contributor.authorCHANOCK, S. J.
dc.contributor.authorROTHMAN, N.
dc.contributor.authorHARTGE, P.
dc.contributor.authorSKIBOLA, C. F.
dc.date.accessioned2021-01-06T13:28:23Z
dc.date.available2021-01-06T13:28:23Z
dc.date.issued2018-07-15
dc.identifier.issn0008-5472en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/23715
dc.description.abstractEnA growing number of loci within the human leukocyte antigen (HLA) region have been implicated in non-Hodgkin lymphoma (NHL) etiology. Here, we test a complementary hypothesis of "heterozygote advantage" regarding the role of HLA and NHL, whereby HLA diversity is beneficial and homozygous HLA loci are associated with increased disease risk. HLA alleles at class I and II loci were imputed from genome-wide association studies (GWAS) using SNP2HLA for 3,617 diffuse large B-cell lymphomas (DLBCL), 2,686 follicular lymphomas (FL), 2,878 chronic lymphocytic leukemia/small lymphocytic lymphomas (CLL/SLL), 741 marginal zone lymphomas (MZL), and 8,753 controls of European descent. Both DLBCL and MZL risk were elevated with homozygosity at class I HLA-B and -C loci (OR DLBCL = 1.31, 95% CI = 1.06-1.60; OR MZL = 1.45, 95% CI = 1.12-1.89) and class II HLA-DRB1 locus (OR DLBCL = 2.10, 95% CI = 1.24-3.55; OR MZL = 2.10, 95% CI = 0.99-4.45). Increased FL risk was observed with the overall increase in number of homozygous HLA class II loci (P trend < 0.0001, FDR = 0.0005). These results support a role for HLA zygosity in NHL etiology and suggests that distinct immune pathways may underly the etiology of the different NHL subtypes.Significance: HLA gene diversity reduces risk for non-Hodgkin lymphoma. Cancer Res; 78(14); 4086-96. (c)2018 AACR.
dc.language.isoENen_US
dc.subject.enEPICENE
dc.title.enHLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes
dc.title.alternativeCancer Resen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1158/0008-5472.Can-17-2900en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed29735552en_US
bordeaux.journalCancer Researchen_US
bordeaux.page4086-4096en_US
bordeaux.volume78en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue14en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamEPICENE_BPH
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03100050
hal.version1
hal.date.transferred2021-01-06T13:28:34Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.jtitle=Cancer%20Research&amp;rft.date=2018-07-15&amp;rft.volume=78&amp;rft.issue=14&amp;rft.spage=4086-4096&amp;rft.epage=4086-4096&amp;rft.eissn=0008-5472&amp;rft.issn=0008-5472&amp;rft.au=WANG,%20S.%20S.&amp;CARRINGTON,%20M.&amp;BERNDT,%20S.%20I.&amp;SLAGER,%20S.%20L.&amp;BRACCI,%20P.%20M.&amp;rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée